On April 26, 2023 IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, reported an oral presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place in Chicago from June 2-6, 2023 (Press release, In8bio, APR 26, 2023, View Source [SID1234630670]). The oral presentation will highlight new Phase 1 study results evaluating the safety, tolerability and efficacy of INB-200, a potentially promising treatment for newly diagnosed glioblastoma multiforme (GBM).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited that the Phase I trial of INB-200 in GBM has been selected for an oral presentation at ASCO (Free ASCO Whitepaper)," said William Ho, CEO and co-founder of IN8bio. "GBM is a highly aggressive and difficult-to-treat brain cancer, where treatment options have remained largely unchanged for almost two decades. The current median progression-free survival with the standard of care for GBM is 6-7 months and overall survival is only 14-16 months. We believe that our unique approach to solid tumor cancers targeting the DNA damage response with our genetically engineered gamma-delta T cells may eliminate more cancer cells and potentially prolong the time to relapse or death."
Details of the oral presentation are as follows:
Abstract Title: INB-200 Phase I Study of Gene Modified Autologous Gamma-Delta (γδ) T Cells in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) Receiving Maintenance Temozolomide (TMZ)
Abstract #: 2007
Session: S100a – Central Nervous System Tumors
Date and Time: Friday, June 2, 2023, 2:45 PM CDT (3:45 PM EDT)
The abstract will be available on Thursday, May 25 at 5:00 PM EDT on ASCO (Free ASCO Whitepaper).org.
About INB-200
INB-200 is a genetically modified autologous drug resistant immunotherapy (DRI) product candidate for the treatment of solid tumors. This novel platform utilizes genetic engineering to generate chemotherapy resistant gamma delta T cells which can be administered concurrently with standard-of-care treatment in solid tumors. This is a powerful, synergistic treatment approach enabling gamma-delta T cells to persist in the presence of chemotherapy, and maintain their natural ability to recognize, engage and kill cancer cells.
INB-200 is the first genetically engineered gamma-delta T cell therapy to be administered to patients with solid tumors and our initial indication is in GBM.